ArticleNature2026
Membranolytic peptide programs immunogenic cell death for cancer therapy.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remodeling the tumor immune microenvironment: mechanisms of crosstalk between regulated cell death macrophages.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Yueling Yuan *School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0001-6262-3452
Lifang Liang *School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0006-3741-8437
Jie Li *School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0000-0001-5992-3094
Chengrun LiSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0009-1184-3429
Fuxiang WangGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0002-1610-9169
Kai YanMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Chanjuan SuGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0008-5260-526X
Jingxian ChenSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0003-7920-4857
Fan LanGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0006-1252-2852
Zining WuSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0001-5155-7285
Rupei DuSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0009-9407-4054
Yaofeng ZhouSchool of Engineering, Westlake University, Hangzhou, China.ORCID http://orcid.org/0009-0002-4453-4226
Xiongwei XiangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0002-6177-2322
Jueqiong XuGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0006-0591-7477
Huosheng ZhouGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0007-8681-3422
Long ZouGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID http://orcid.org/0009-0006-3880-5383
Zhouming ZhangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.
Yuhao ZhangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0009-0002-8430-1646
Songyin HuangGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Yajing ZhangState Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Penghui ZhouState Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.ORCID http://orcid.org/0000-0003-0519-461X
Tianmeng SunKey Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, and Institute of Immunology, Jilin University, Changchun, China.ORCID http://orcid.org/0000-0003-2261-4532
Kaiting YangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.ORCID http://orcid.org/0000-0001-9328-5655
Zhibin ZhaoMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0003-0691-2556
Zhexiong LianMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0002-9525-1421
Shiyan XiaoDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, China. xiaosy@ustc.edu.cn.ORCID http://orcid.org/0000-0003-1159-1224
Jianjun ChengSchool of Engineering, Westlake University, Hangzhou, China. chengjianjun@westlake.edu.cn.ORCID http://orcid.org/0009-0000-5867-8015
Yan BaoGuangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. baoy5@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-5072-9428
Menghua XiongSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China. xiongmh@scut.edu.cn.ORCID http://orcid.org/0000-0003-0020-5965
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rational design for facilitating innovative cell death modes can substantially aid advances in antitumour therapy
Indexed as
Cell MembraneImmunogenic Cell DeathNeoplasmsPeptidesAnimalsAntigen PresentationCell Line, TumorDendritic CellsFemaleHistocompatibility Antigens Class IHumansHydrogen-Ion ConcentrationImmune Checkpoint InhibitorsLysosomesMiceT-LymphocytesHistocompatibility Antigens Class IImmune Checkpoint InhibitorsPeptides
Identifiers
PMID
42557318What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.